Spike Protein, Microplastics, and Your Liver: The NAC/Nattokinase Fix

🎧 ▶️ Press the play button below to listen in English.

Introduction

You open your patient portal and scan the bloodwork results. Most numbers are in the green. Then you see them: ALT and AST, your liver enzymes, flagged in yellow or red.

Your mind races. You’re not a heavy drinker. You don’t have hepatitis. Your weight is reasonable. You eat a Mediterranean-ish diet.

At your follow-up, the doctor offers a familiar shrug. “Probably a little fatty liver. Try to cut carbs and come back in six months.”

You walk away with a lingering anxiety and precisely zero concrete steps to take. You’ve just joined the silent majority.

The traditional diagnostic algorithm for elevated liver enzymes—rule out alcohol, rule out viruses, blame obesity—is struggling to explain a growing clinical picture.

Studies confirm the rising prevalence of ‘lean NAFLD’ in those without standard risk factors. At the same time, microplastics have been definitively identified in human liver tissue, and persistent spike protein has been found in immune cells over a year after infection.

While large-scale population studies are still emerging, the mechanistic case for a new, multi-factorial hepatic stress—driven not by calories but by chronic, low-grade inflammatory and microvascular insults—is increasingly difficult to ignore.

If you are in that group—the lean, active non-drinker with no viral hepatitis and a clean ultrasound, staring at a liver enzyme result that makes no sense—you already know the standard advice fails. “Eat less, move more” doesn’t land when you already do.

The problem isn’t your lifestyle. It’s that the diagnostic model hasn’t caught up to the biology of what may be irritating your liver.

While large-scale epidemiological studies are still catching up, the converging mechanistic picture—persistent viral fragments, microplastic accumulation, and microvascular fibrin deposition—offers a new lens. And with that lens comes a rational, low-risk therapeutic hypothesis worth discussing with a knowledgeable clinician.

Instead of waiting and watching your enzymes drift higher, you can ask a different question: What if my liver cells are inflamed by oxidative overload and starved of oxygen at the microvascular level?

That question points to two specific, research-backed natural compounds that target those exact mechanisms. They don’t come in an expensive prescription bottle. They are N-Acetylcysteine (NAC) and Nattokinase. They are not a cure-all. But for this specific, emerging phenotype of unexplained transaminitis, they represent one of the most logically coherent, low-risk interventions on the table.

---

Part 1: The Old Algorithm Is Dead

For a generation, the medical flowchart for elevated liver enzymes was simple.

Rule out Hepatitis A, B, and C. If negative, ask about alcohol. If the patient drinks little, prescribe weight loss. The assumed culprit was simple metabolic overload—too much sugar and fat accumulating in liver cells.

This algorithm is now dangerously incomplete.

Today, a slender, active 35-year-old who rarely drinks can have the liver enzymes of a chronic alcoholic. This person isn’t eating their way to liver damage. They are filtering their way there. The year 2026 liver is under siege from three modern forces that standard testing and standard advice were never designed to see.

---

Part 2: The Three New Horsemen of Hepatic Stress

Think of your liver as a master water filter. Its job is to screen every single thing that enters your bloodstream from your gut and environment, neutralizing toxins and packaging waste for removal. For centuries, this filter handled a relatively predictable organic load.

Today, that has changed completely. Three new insults are driving a chronic, low-grade inflammatory fire inside our livers.

1. The Plastic Infiltration

We live in a world saturated with plastic. It’s in our clothes, our food packaging, our water, and the air we breathe. For years, the question was whether microplastics simply passed through us. The answer, revealed in 2024 and 2025 tissue studies, is a definitive no.

Tiny microplastic and nanoplastic particles are now being found lodged in the very architecture of the human liver.

These particles are not inert. To your immune system, a small plastic shard embedded in delicate hepatic tissue looks like a foreign invader. The liver’s resident immune cells, called Kupffer cells, mount a constant, frustrated attack. This creates a state of perpetual, low-grade inflammation.

Imagine constantly rubbing a grain of sand in your eye. The irritation never resolves. This is your liver on microplastics: chronically inflamed, leaking enzymes from irritated cells, with no infection to fight and no toxin to metabolize. Our great-grandparents filtered spring water; we filter chemical dust.

Related:

1. Tiny Plastics, Big Problems: What You Must Know
2. Invisible Killers: The Startling Truth About Microplastics That’s Everywhere
3. Microplastics in Breast Milk
4. Microplastics found in the Human Placenta, Intestines and Sputum

2. The Persistent Viral Fragment

The pandemic reshaped our understanding of viral illness. One of the most unsettling discoveries is the phenomenon of persistent viral protein.

Research using highly sensitive detection methods has found fragments of the SARS-CoV-2 spike protein circulating in blood and hiding in immune cells months and even years after a single infection or vaccination. This isn’t a question of acute illness; it’s a question of sluggish biological cleanup.

The liver is uniquely vulnerable to this persistent debris. Liver cells are rich in ACE2 receptors, the very docking station the virus uses to enter cells. The presence of lingering spike protein keeps a specific fire smoldering. It continuously activates the liver’s macrophages, creating a slow-motion immune civil war called “persistent immune surveillance.”

Your liver isn’t infected with a replicating virus. It’s just stuck with the non-biodegradable trash. And it’s inflamed because of it.

3. The Sludge in the Pipes (Microclots)

This is the most insidious and overlooked factor. We now understand that a core pathology of post-viral syndromes is in the blood itself.

The spike protein can interact with blood components, inducing the formation of abnormal, highly resilient microclots. These aren’t the normal clots your body creates and then dissolves with ease.

Research by scientists like Dr. Resia Pretorius has identified them as “amyloid-like” structures—dense, misfolded protein masses that resist standard enzymatic breakdown.

Your liver is an ultra-fine vascular network. It’s filled with microscopic highways called sinusoids, only wide enough for red blood cells to pass in a single file.

Imagine these microclots as a fleet of bumper-to-bumper trucks stuck on those tiny roads. Blood flow to the downstream liver cells is cut off. These cells aren’t sick; they are suffocating. When a cell dies from lack of oxygen (hypoxia), it bursts open, spilling ALT and AST enzymes into your blood.

This is not metabolic dysfunction. It’s a microvascular plumbing failure. Your ultrasound appears clear because the organ appears structurally sound at a distance. But up close, entire neighborhoods of liver cells are in hypoxic crisis.

---

Part 3: The Dual-Key Solution

A three-headed problem requires a targeted, multi-pronged answer.

If the roots are due to oxidative stress from plastic/viral debris, glutathione depletion, and microvascular sludge, the solution must be both a chemical protector and a biological plumber. This is the precise role of NAC and Nattokinase.

NAC: The Master Shield & Detox Recharger

N-Acetylcysteine (NAC) is not a vitamin. It’s a rate-limiting precursor. Your body takes NAC and converts it into glutathione, arguably the most important antioxidant inside every cell. The liver uses glutathione like a bouncer to grab toxins and march them out of the body.

This is so clinically potent that hospitals use high-dose intravenous NAC to save patients from lethal Tylenol overdoses that cause acute liver failure.

Why is this relevant to your chronically elevated enzymes?

Your liver’s daily battle against microplastics and stubborn viral fragments imposes a brutal, unrelenting drain on your glutathione reserves. It’s like running a factory on a skeleton crew 24/7. Eventually, the workers collapse. When glutathione is chronically low, your liver cells are naked and vulnerable to free radical damage. They slowly leak enzymes simply from structural fatigue.

Taking NAC is like sending in a fresh, fully-staffed night crew. It replenishes glutathione, slashing the oxidative stress that scars and irritates liver cells.

But NAC has a second, hidden superpower.

NAC is a mucolytic agent, meaning it chemically slices apart thick mucus by breaking up sulfur bonds. In the post-viral liver landscape, this is critical. Pathological debris often gets coated in a slimy, protective biofilm-like mucus in the tiny bile ducts.

NAC thins this sludge. It turns dense, stuck gunk into a flowing liquid that can be excreted. It physically unclogs the liver’s drainage pipes.

Nattokinase: The Microvascular Dredger

If NAC is the cellular bodyguard, Nattokinase is the street-sweeper for your blood. It’s a powerful enzyme derived from natto, a traditional Japanese fermented soybean dish.

Nattokinase is nature’s most effective fibrinolytic enzyme. “Fibrinolytic” means it breaks down fibrin, the protein mesh that forms clots.

Unlike aggressive pharmaceutical blood thinners that simply prevent new clot formation, Nattokinase actively degrades existing clots. It directly dismantles the end-stage, resistant amyloid microclots that conventional plasmin (your body’s natural cleaner) cannot dissolve.

For your liver, this is the mechanism that restores life. Nattokinase gently enters the hepatic sinusoids and starts digesting the fibrin microclogs. It reopens the microscopic roads, allowing nourishing, oxygen-rich blood to finally flow back to the hypoxic cells.

A liver cell saved from suffocation stops spilling ALT. It’s as direct as that.

Beyond its enzymatic clot-busting, Nattokinase also reduces blood viscosity. It changes the “thickness” of your blood, helping it glide more easily through the delicate liver filter without stalling. For a liver trying to process sludgy, plastic-filled, spike-protein-laden blood, simply making the flow more fluid is a massive relief.

---

Part 4: The Elegant Dance – Why Timing Is Everything

You could take these two compounds, and they would help. But to unlock a true synergy—a 1+1=3 effect—you must understand their chemical conversation.

• NAC is a disulfide bond breaker. Pathological fibrin microclots are often hardened and stabilized by abnormal cross-links. NAC helps “unlock” the protective outer shell of these clots, loosening the target.
• Nattokinase is the protease. Once NAC weakens the clot’s structure, Nattokinase can cleave it into biodegradable fragments much more efficiently.

Think of NAC as the solution that loosens a rusted bolt. Nattokinase is the wrench that removes it. Without loosening it first, you risk snapping the wrench.

The Critical 2-Hour Separation Rule

This partnership also requires a boundary. NAC is a reducing agent. If you swallow both pills at the exact same moment, the NAC can potentially degrade the delicate Nattokinase enzyme in your stomach before it’s even absorbed.

You must separate them.

This timing creates a therapeutic wave. The stagger ensures each compound does its job at peak efficiency without interfering with the other.

---

Part 5: Your 30-Day Hepatic Reset Protocol

This is not medical advice for advanced disease. This is the functional, restorative protocol for the “worried well”—the millions with unexplained ALT/AST lingering between 40 and 100 U/L, brain fog, and post-viral fatigue.

The Morning Plumber (On Waking):

• What: Nattokinase 2000 FU – 4000 FU (look for the NSK-SD strain, the clinical-grade standard)
• How: Take with a large glass of water on a completely empty stomach.
• Why: An empty stomach ensures the enzyme is absorbed intact into your bloodstream, not wasted digesting food.
• Then wait: Hold all food, coffee, and other supplements for at least 60 minutes.

The Midday Protector (Between Meals):

• What: NAC 600 mg. Pair with 500 mg Vitamin C and a source of Selenium (like 1 Brazil nut).
• When: Mid-morning or mid-afternoon. Crucially, this must be at least 2 hours after your Nattokinase and at least 1 hour before or after meals.
• Why: Selenium is the fuel for the glutathione engine you’re building with NAC. Vitamin C helps recycle and keep glutathione active.

Amazon affiliate links below.

• BulkSupplements.com N-Acetyl L-Cysteine Capsules – 600mg per Capsule
• Bronson Vitamin C 500 MG 
• Nutricost Selenium 200mcg

The Critical Support: Hydration
This step is non-negotiable. As Nattokinase clears microclots from your liver and NAC detoxifies your tissues, these waste products are carried into your blood for kidney filtration.

If you are dehydrated, this toxic dump stalls. You will feel terrible—headache, fatigue, muscle aches. This is known as a Herxheimer reaction.

• Drink: A minimum of 2.5 to 3 liters of mineralized water, daily.
• Mindset: Every glass is flushing the liberated sludge out of your system for good.

---

Part 6: What You’ll Feel (The Healing Timeline)

Monitoring your progress requires a shift from lab numbers alone to physical sensation, as tissue healing often precedes normalization of test results.

• Days 3-5: Your urine may appear slightly darker or have a stronger odor. This isn’t a bad sign; it’s often the first wave of fibrin degradation products and liberated metabolic waste being excreted.
• Day 14: The “Brain Fog” Door Opens. As the hepatic filter clears and systemic microclots recede, the low-grade endotoxemia that clouds cognition diminishes. You may notice sharper recall and quicker thinking.
• Day 30: A Subtle Energy Shift. Chronic fatigue, often driven by hypoxic liver tissue and poor detoxification, begins to lift. Energy becomes more stable, not the wired-and-crashed cycle.
• Week 8: Recheck Your Labs. Don’t test at 30 days; you’ll likely catch the liver in mid-repair with frustratingly unchanged numbers. Give it a full 8 weeks for true hepatocyte regeneration. You will typically see AST drop first (it clears the blood faster), with ALT settling into an optimal range (low 20s) later—signaling true cellular peace.

---

A Word of Caution (When This Fix Is Not for You)

This protocol powerfully changes blood dynamics and oxidative chemistry. Do not use it if:

• You have been diagnosed with advanced cirrhosis (F4 fibrosis). Changing portal blood pressure dynamics requires medical supervision.
• You are on prescription blood thinners (Warfarin, Eliquis) without a doctor’s approval. Nattokinase is a natural anticoagulant, and the synergy requires careful monitoring.
• You have a known bile duct obstruction. NAC’s mucolytic power might increase pressure behind a heavy stone blockage.

---

Conclusion: The Takeaway

You are not broken. Your liver is not failing from a mysterious disease. It’s simply overwhelmed by a workload no human organ in history has ever faced: a sludgy, plastic-laced, microclot-filled blood supply.

The standard model says wait and watch it get worse. The biological reality says fix the flow and recharge the filter.

A Note on Transparency and the Evolving Evidence

This protocol does not yet rest on a large, prospective, double-blind clinical trial specifically designed to test NAC and Nattokinase for unexplained transaminitis in the context of microplastic accumulation, persistent spike protein, and microclot pathology. That trial does not exist. And if history is any guide, it may take years for the research machinery to design, fund, execute, and publish it.

The framework offered here is a product of mechanistic reasoning—the practice of connecting established biochemical, hematological, and immunological principles across disciplines to generate a biologically plausible, low-risk intervention. NAC’s glutathione-repleting capacity is decades-proven in emergency medicine.

Nattokinase’s fibrinolytic activity is well-documented in the cardiovascular literature. The pathways by which oxidative stress and microvascular hypoxia damage hepatocytes are not speculative; they are textbook hepatology.

What is new is the synthesis. The hypothesis that these two compounds, properly timed, may address a specific, emerging phenotype of liver stress for which the standard diagnostic algorithm currently offers no answers.

This is precisely the kind of cross-disciplinary inference at which modern AI reasoning tools excel—not replacing clinical evidence, but bridging the gap when waiting for perfect data means offering patients nothing.

This transparency matters. You deserve to know when you are being offered a logical therapeutic hypothesis rather than a guideline-endorsed standard of care.

That means two things.

First, this article is an educational starting point, not a prescription. It is designed to equip you with a coherent, biologically grounded framework you can take to your doctor and say, “Here’s what I’m learning. Does this make sense for my situation? Can we monitor my enzymes and see if it helps?”

Second, never stop following with your physician. Serial liver enzyme monitoring, symptom tracking, and open dialogue with a clinician who respects your agency are non-negotiable parts of this process. The protocol is low-risk, but no protocol is zero-risk, and individual variables—undiagnosed biliary obstruction, advanced fibrosis, concurrent anticoagulant use—can shift the calculus.

The goal here is not to replace the medical establishment. It is to offer the millions of people with unexplained, elevated liver enzymes a rational place to start the conversation while the formal evidence base catches up to what biochemistry and clinical observation are already suggesting.

Summary: The Core Takeaways

• The New Problem: Modern elevated liver enzymes are a microvascular and oxidative stress disorder, driven by microplastics, persistent viral debris, and fibrin microclots.
• The Old Model Fails: Cutting carbs and alcohol alone won’t fix suffocating liver cells or dissolve hardened biological sludge.
• NAC is the Rebuilder: It replenishes the liver’s master antioxidant shield (glutathione) and thins the pathological mucus trapping toxins in your bile ducts.
• Nattokinase is the Unclogger: It acts as a gentle biological drain cleaner, digesting the abnormal microclots that starve your liver cells of oxygen.
• The Synergy is Chemical: NAC loosens the pathological protein targets, and Nattokinase cleaves them away. But they must be taken a minimum of 2 hours apart to work their magic.
• Hydration is the Excretor: Water is the final step, flushing the mobilized debris out of your body. Without it, the protocol stalls.
• Your Liver is a River Delta: It’s the sump for everything in your body. Keep the water clean and the current flowing. NAC and Nattokinase, properly harnessed, are how you do it.

Don’t Get Sick!

About Dr. Jesse Santiano, MD

Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.

💡 Support This Work

Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.

🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!

Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.

Related:

1. N-Acetylcysteine (NAC) for COVID-19
2. How to Dose Nattokinase, Bromelain and NAC
3. The I-RECOVER Post-Vaccine Treatment Protocol
4. Bromelain and NAC: Can They Break Down the SARS-CoV-2 Spike Protein?
5. Colloidal bismuth and NAC inhibit SARS-CoV-2 replication
6. 6 Potential Uses of the Bismuth + NAC combination
7. How To Interpret The 10,800 FU Nattokinase Findings Safely
8. Could Nattokinase Be Useful In Preventing Alzheimer’s Dementia?
9. An Unusual Case of Parkinsonism Improvement After Nattokinase Use
10. Laboratory Studies on Nattokinase and Abnormal Protein Aggregates
11. Nattokinase and Stroke Research: Understanding the Evidence
12. A Laboratory Study on Nattokinase and the S1 Spike Protein Fragment
13. Laboratory Study Shows Nattokinase Can Break Down Spike Protein Fragments
14. Could Nattokinase Be Useful In Preventing Alzheimer’s Dementia?
15. Nattokinase Degrades Amyloids and Prions
16. Natto: An application of the 80-20 Rule
17. Should you take nattokinase on an empty stomach?
18. How to stop bleeding if on nattokinase
19. Natto: An application of the 80-20 Rule
20. How I Made and Appreciate Natto
21. Insulin Resistance and Atherosclerosis and the Nattokinase Solution
22. Protective Effects of Nattokinase against Strokes
23. High-Dose Nattokinase to Shrink Atherosclerosis and Lower Blood Lipids
24. Nattokinase is Nontoxic with a High Safety Margin
25. The Outstanding Vascular Effects and Dose of Nattokinase
26. Soy Foods Do Not Increase Breast Cancer Risk

References:

1. Ye, Q., Zou, B., Yeo, Y. H., Li, J., Huang, D. Q., Wu, Y., Yang, H., Liu, C., Kam, L. Y., Tan, X. X. E., Chien, N., Trinh, S., Henry, L., Stave, C. D., Hosaka, T., Cheung, R. C., & Nguyen, M. H. (2020). Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, *5*(8), 739–752. https://doi.org/10.1016/S2468-1253(20)30077-7
2. Kulkarni, A. V., Kumar, P., Tevethia, H. V., Premkumar, M., Arab, J. P., Candia, R., Talukdar, R., Sharma, M., Qi, X., Rao, P. N., & Reddy, D. N. (2021). Systematic review with meta-analysis: Liver manifestations and outcomes in COVID-19. Alimentary Pharmacology & Therapeutics, *54*(5), 563–577. https://pmc.ncbi.nlm.nih.gov/articles/PMC7361465/
3. Horvatits, T., Tamminga, M., Liu, B., Sebode, M., Carambia, A., Fischer, L., Püschel, K., Huber, S., & Fischer, E. K. (2022). Microplastics detected in cirrhotic liver tissue. EBioMedicine, *82*, 104147. https://doi.org/10.1016/j.ebiom.2022.104147
4. Bansal, S., Perincheri, S., Fleming, T., Poulson, C., Tiffany, B., Bremner, R. M., & Mohanakumar, T. (2021). Cutting edge: Circulating exosomes with COVID spike protein are induced by BNT162b2 vaccination prior to development of antibodies. Journal of Immunology, *207*(10), 2405–2410. https://doi.org/10.4049/jimmunol.2100637
5. Patterson, B. K., Francisco, E. B., Yogendra, R., Long, E., Pise, A., Rodrigues, H., Hall, E., Herrera, M., Parikh, P., Guevara-Coto, J., Triche, T. J., Scott, P., Hekmati, S., Maglinte, D., Chang, X., Mora-Rodríguez, R. A., & Mora, J. (2022). Persistence of SARS CoV-2 S1 protein in CD16+ monocytes up to 15 months post-infection. Frontiers in Immunology, *13*, Article 830821. https://pmc.ncbi.nlm.nih.gov/articles/PMC8784688/
6. Röltgen, K., Nielsen, S. C. A., Silva, O., Younes, S. F., Zaslavsky, M., Costales, C., Yang, F., Wirz, O. F., Solis, D., Hoh, R. A., Wang, A., Arunachalam, P. S., Colburg, D., Zhao, S., Haraguchi, E., Lee, A. S., Shah, M., Manohar, M., Chang, I., … Boyd, S. D. (2022). Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell, *185*(6), 1025–1040.e14. https://doi.org/10.1016/j.cell.2022.01.018
7. Swank, Z., Senussi, Y., Manickas-Hill, Z., Yu, X. G., Li, J. Z., Alter, G., & Walt, D. R. (2023). Persistent circulating severe acute respiratory syndrome coronavirus 2 spike is associated with post-acute coronavirus disease 2019 sequelae. Clinical Infectious Diseases, *76*(3), e487–e490. https://doi.org/10.1093/cid/ciac722
8. Kell, D. B., Laubscher, G. J., & Pretorius, E. (2022). A central role for amyloid fibrin microclots in long COVID/PASC: Origins and therapeutic implications. Biochemical Journal, *479*(4), 537–559. https://doi.org/10.1042/BCJ20220016
9. Pretorius, E., Venter, C., Laubscher, G. J., Kotze, M. J., Oladejo, S. O., Watson, L. R., Rajaratnam, K., Watson, B. W., & Kell, D. B. (2022). Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). Cardiovascular Diabetology, *21*, Article 148. https://doi.org/10.1186/s12933-022-01579-5
10. Pretorius, E., Vlok, M., Venter, C., Bezuidenhout, J. A., Laubscher, G. J., Steenkamp, J., & Kell, D. B. (2021). Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovascular Diabetology, *20*, Article 172. https://doi.org/10.1186/s12933-021-01359-7
11. Beyzaei Z, Geramizadeh B, Bagheri Z, Karimzadeh S, Weiskirchen R. Microplastics in focus: a silent disruptor of liver health- a systematic review. Front Pharmacol. 2025 Dec 1;16:1721644. doi: 10.3389/fphar.2025.1721644. PMID: 41403441; PMCID: PMC12703192. https://pmc.ncbi.nlm.nih.gov/articles/PMC12703192/
12. Mercado-Gómez, M., Prieto-Fernández, E., Goikoetxea-Usandizaga, N. et al. The spike of SARS-CoV-2 promotes metabolic rewiring in hepatocytes. Commun Biol 5, 827 (2022). https://doi.org/10.1038/s42003-022-03789-9
13. Pretorius, E., et al. (2021). “Prevalence of Amyloid Blood Clots in COVID-19 Plasma and Long COVID/PASC.” Cardiovascular Diabetology, 20, 172. (Defines the resistant microclot pathology). https://pmc.ncbi.nlm.nih.gov/articles/PMC9356426/
14. Ashokan, A.K., Mohanasrinivasan, V. Insights on the therapeutic potential of fibrinolytic enzymes, emphasis on Nattokinase and its enhanced production using advanced technologies: a critical review. Discov Appl Sci 7, 653 (2025). https://doi.org/10.1007/s42452-025-07102-1
15. Samuni, Y., et al. (2013). “The chemistry and biological activities of N-acetylcysteine.” Biochimica et Biophysica Acta (BBA) – General Subjects, 1830(8), 4117-4129. (Details the glutathione regeneration and disulfide bond cleavage mechanisms). https://www.sciencedirect.com/science/article/abs/pii/S030441651300144X
16. Kellum, J. A., & Lameire, N. (2023). “KDIGO Clinical Practice Guideline for Acute Kidney Injury and Hepato-Renal Protection.” Kidney International Supplements, 13(1), 1-110. (While focused on AKI, this outlines the critical metabolic role of NAC in preventing organ oxidative injury). https://r.search.yahoo.com/_ylt=AwrhdkZWGO1pzFYBnGUPxQt.;_ylu=Y29sbwNiZjEEcG9zAzIEdnRpZAMEc2VjA3Ny/RV=2/RE=1778355543/RO=10/RU=https%3a%2f%2fkdigo.org%2fwp-content%2fuploads%2f2026%2f03%2fKDIGO-2026-AKI-AKD-Guideline-Public-Review-Draft-March-2026.pdf/RK=2/RS=WBLupUpOuZrTE_QSJrbwq.BPVCA-
17. Aldini, G., et al. (2018). “N-Acetylcysteine as an antioxidant and disulfide breaking agent: the reasons why.” Free Radical Research, 52(7), 751-762. (Explains the protein unfolding action of NAC on pathological polymers). https://www.tandfonline.com/doi/full/10.1080/10715762.2018.1468564
18. Wang, Y., Liu, S., Liu, H., Li, W., Lin, F., Jiang, L., Li, X., Xu, P., Pan, X., Liu, J., Gong, F., Zhang, L., Wang, Y., & Yang, H. (2020). SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. Journal of Hepatology, *73*(4), 807–816. https://doi.org/10.1016/j.jhep.2020.05.002

Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.

© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment

As an Amazon Associate, I earn from qualifying purchases